Sudarshan Pharma Industries (543828) Q2 2026 earnings summary

Executive summary

• Unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2025 were approved and reviewed without qualification by auditors.

• The company voluntarily adopted Ind AS from April 1, 2025, with restated prior period figures.

Financial highlights

• Standalone revenue from operations for Q2 FY26 was ₹16,700.63 lakhs, up from ₹12,361.92 lakhs in Q2 FY25; consolidated revenue was ₹16,886.70 lakhs for Q2 FY26.

• Standalone net profit for Q2 FY26 was ₹440.03 lakhs, compared to ₹541.61 lakhs in Q2 FY25; consolidated net profit was ₹387.25 lakhs for Q2 FY26.

• Basic and diluted EPS (standalone) for Q2 FY26 stood at ₹0.18, while consolidated EPS was ₹0.16.

• Total standalone assets as of 30th September 2025 were ₹48,859.79 lakhs; consolidated assets were ₹50,689.51 lakhs.

Outlook and guidance

• The Board approved raising up to ₹1,500 crores via equity, GDRs, FCCBs, or other securities; in-principle approval for FCCB issuance up to USD 35 million was received.